Science Applications (0V9N) Share Forecast & Price Target
0V9N Analyst Ratings
0V9N Stock 12 Month Forecast
Average Price Target
$133.71▼(-12.19% Downside)Detailed List of Analyst Forecasts
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| Noah Poponak | Goldman Sachs | $103→$99 | sell | -34.98%Downside | Reiterated | 10/11/26 | ||
| Gautam Khanna | TD Cowen | $140 | hold | -8.06%Downside | Reiterated | 10/05/26 | ||
| Seth Seifman | J.P. Morgan | $150 | hold | -1.49%Downside | Reiterated | 09/03/26 | ||
| Sheila Kahyaoglu | Jefferies | $130→$140 | hold | -8.06%Downside | Assigned | 09/01/26 | ||
| Jonathan Siegmann CFA | Stifel Nicolaus | $137→$154 | buy | 1.14%Upside | Reiterated | 09/01/26 | ||
| Tobey Sommer | Truist Financial | $110→$130 | hold | -14.63%Downside | Reiterated | 09/01/26 | ||
| Gavin Parsons | UBS | $108→$123 | hold | -19.22%Downside | Reiterated | 09/01/26 | ||
| Louie DiPalma | William Blair | ― | hold | ― | Reiterated | 08/31/26 | ||
| John Godyn | Citi | $132 | buy | -13.31%Downside | Assigned | 07/01/26 | ||
 Unknown AnalystNot Ranked | Bernstein | ― | hold | ― | Reiterated | 06/03/26 | ||
| Matthew Akers | Exane BNP Paribas | $95 | hold | -37.61%Downside | Initiated | 05/27/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| Noah Poponak | 10/11/26 | $103→$99 | sell | -34.98%Downside | Reiterated | Goldman Sachs | ||
| Gautam Khanna | 10/05/26 | $140 | hold | -8.06%Downside | Reiterated | TD Cowen | ||
| Seth Seifman | 09/03/26 | $150 | hold | -1.49%Downside | Reiterated | J.P. Morgan | ||
| Sheila Kahyaoglu | 09/01/26 | $130→$140 | hold | -8.06%Downside | Assigned | Jefferies | ||
| Jonathan Siegmann CFA | 09/01/26 | $137→$154 | buy | 1.14%Upside | Reiterated | Stifel Nicolaus | ||
| Tobey Sommer | 09/01/26 | $110→$130 | hold | -14.63%Downside | Reiterated | Truist Financial | ||
| Gavin Parsons | 09/01/26 | $108→$123 | hold | -19.22%Downside | Reiterated | UBS | ||
| Louie DiPalma | 08/31/26 | ― | hold | ― | Reiterated | William Blair | ||
| John Godyn | 07/01/26 | $132 | buy | -13.31%Downside | Assigned | Citi | ||
| Unknown AnalystNot Ranked | 06/03/26 | ― | hold | ― | Reiterated | Bernstein | ||
| Matthew Akers | 05/27/26 | $95 | hold | -37.61%Downside | Initiated | Exane BNP Paribas |
Best Analysts Covering Science Applications
Copying Jonathan Siegmann CFA's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +7.34% per trade.
Copying John Godyn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +44.56% per trade.
Copying Jonathan Siegmann CFA's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +51.38% per trade.
0V9N Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 2 | 1 | 1 |
| Hold | 9 | 10 | 7 | 8 | 6 |
| Sell | 1 | 1 | 1 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 13 | 14 | 10 | 11 | 9 |
In the current month, 0V9N has received 1 Buy Ratings, 6 Hold Ratings, and 2 Sell Ratings. 0V9N average Analyst price target in the past 3 months is 133.71.
0V9N Financial Forecast
0V9N Earnings Forecast
Next quarter’s earnings estimate for 0V9N is $2.35 with a range of $2.27 to $2.41. The previous quarter’s EPS was $3.01. 0V9N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 49.22% of the time in the same period. In the last calendar year 0V9N has Performed in-line its overall industry.
0V9N Sales Forecast
Next quarter’s sales forecast for 0V9N is $1.82B with a range of $1.78B to $1.84B. The previous quarter’s sales results were $1.88B. 0V9N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 53.85% of the time in the same period. In the last calendar year 0V9N has Performed in-line its overall industry.